No insider purchase over the last 90 days. The latest was filed 18 Jun 2026.
Every trade that managers of Artrya Limited disclose to ASX is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for Artrya Limited logged 14 filings by 8 insiders.
Open-market activity splits into 1 purchase totalling €459k and 2 sales totalling €840k; 1 insider sit on the buying side and 1 insider on the selling side. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €840k, sold by Bernie Ridgeway and made public on 11 June 2026 (0.025% of market cap). On the buying side, the filings list 1 senior executive among the declarants.
Compared with its exchange (2,222 companies, median 3 filings), a count of 14 filings is above the norm. Since 2026, the database holds 1 purchase and 2 sales by insiders of the company.
The clock since the last published purchase (18 June 2026) now reads 121 days. Filings reach the ASX feed a median of 2 days after the trade. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
This summary is built from ASX disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Artrya Limited Strong Buy (bullish), based on 4 analysts. Average price target: A$6.24.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
14 of 14 declarations
Artrya Limited is a company listed on the XASX, focused on developing technological solutions for cardiac health. It aims to improve clinical outcomes through digital innovation.